Physician profile
Eric J Cohen
NPI 1508950163
$8,750.95
in general payments reported to CMS, 2019-2025
33 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 90% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,026 · 2020: $888 · 2021: $1,622 · 2022: $822 · 2023: $806 · 2024: $810 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $1,851.91 | 2019-2024 | Trudi Nav Cable |
| Intersect Ent, INC. | $1,347.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $1,074.00 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $708.77 | 2019-2025 | |
| Optinose US, INC. | $581.61 | 2019-2025 | |
| Spirair, INC. | $362.92 | 2025 | Turbalign, Septalign |
| Kaleo, INC. | $305.09 | 2022-2024 | Auvi-Q |
| Inspire Medical Systems, INC. | $250.06 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $233.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $192.93 | 2020-2024 | Tezspire |
| Neurent Medical Limited | $172.98 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Novartis Pharmaceuticals Corporation | $168.58 | 2022-2024 | |
| Merz North America, INC. | $151.34 | 2021 | |
| Integra Lifesciences Corporation | $140.73 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Takeda Pharmaceuticals U.S.A., INC. | $135.12 | 2023-2025 | Cuvitru, Hyqvia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $125.62 | 2024-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $111.96 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $102.31 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $95.66 | 2023-2024 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $88.78 | 2019 | |
| Stryker Corporation | $87.57 | 2022-2025 | Scopis Ent |
| Grifols USA, LLC | $82.32 | 2025 | Xembify |
| Medtronic, INC. | $66.97 | 2021-2025 | Propel, Sinuva |
| Alk-Abello, INC | $56.09 | 2019 | |
| Covis Pharma Gmbh | $49.18 | 2021 | |
| Amgen INC. | $40.80 | 2024-2025 | Tezspire |
| Medtronic USA, INC. | $33.14 | 2020 | |
| Octapharma USA, INC. | $25.62 | 2025 | Panzyga |
| Csl Behring | $24.57 | 2023 | Haegarda |
| Biocryst US Sales Co., LLC | $22.70 | 2024 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $21.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.39 | 2022 | |
| Phadia US INC. | $18.40 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.